Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)
X Xu, KL Poulsen, L Wu, S Liu, T Miyata… - Signal transduction and …, 2022 - nature.com
Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive …
Current options and future directions for NAFLD and NASH treatment
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
worldwide, with a broad spectrum ranging from simple steatosis to advanced stage of …
Hepatocyte phosphatase DUSP22 mitigates NASH-HCC progression by targeting FAK
C Ge, J Tan, X Dai, Q Kuang, S Zhong, L Lai… - Nature …, 2022 - nature.com
Nonalcoholic steatohepatitis (NASH), a common clinical disease, is becoming a leading
cause of hepatocellular carcinoma (HCC). Dual specificity phosphatase 22 (DUSP22, also …
cause of hepatocellular carcinoma (HCC). Dual specificity phosphatase 22 (DUSP22, also …
Lipid droplets are intracellular mechanical stressors that impair hepatocyte function
Matrix stiffening and external mechanical stress have been linked to disease and cancer
development in multiple tissues, including the liver, where cirrhosis (which increases …
development in multiple tissues, including the liver, where cirrhosis (which increases …
Vitamin B2 enables regulation of fasting glucose availability
PM Masschelin, P Saha, SA Ochsner, AR Cox, KH Kim… - Elife, 2023 - elifesciences.org
Flavin adenine dinucleotide (FAD) interacts with flavoproteins to mediate oxidation-
reduction reactions required for cellular energy demands. Not surprisingly, mutations that …
reduction reactions required for cellular energy demands. Not surprisingly, mutations that …
FXR and NASH: an avenue for tissue-specific regulation
NASH is within the spectrum of NAFLD, a liver condition encompassing liver steatosis,
inflammation, hepatocyte injury, and fibrosis. The prevalence of NASH-induced cirrhosis is …
inflammation, hepatocyte injury, and fibrosis. The prevalence of NASH-induced cirrhosis is …
Xenobiotic-induced aggravation of metabolic-associated fatty liver disease
Metabolic-associated fatty liver disease (MAFLD), which is often linked to obesity,
encompasses a large spectrum of hepatic lesions, including simple fatty liver …
encompasses a large spectrum of hepatic lesions, including simple fatty liver …
[HTML][HTML] The role of nuclear receptors in the pathogenesis and treatment of non-alcoholic fatty liver disease
Z Yang, A Danzeng, Q Liu, C Zeng, L Xu… - … Journal of Biological …, 2024 - ncbi.nlm.nih.gov
Non-alcoholic fatty liver disease (NAFLD) is a global health burden closely linked to insulin
resistance, obesity, and type 2 diabetes. The complex pathophysiology of NAFLD involves …
resistance, obesity, and type 2 diabetes. The complex pathophysiology of NAFLD involves …
A critical role for HNF4α in polymicrobial sepsis-associated metabolic reprogramming and death
C Van Dender, S Timmermans… - EMBO Molecular …, 2024 - embopress.org
In sepsis, limited food intake and increased energy expenditure induce a starvation
response, which is compromised by a quick decline in the expression of hepatic PPARα, a …
response, which is compromised by a quick decline in the expression of hepatic PPARα, a …
Nanodrug delivery systems for metabolic chronic liver diseases: advances and perspectives
F Athanasopoulou, M Manolakakis, S Vernia… - …, 2023 - Taylor & Francis
Nanomedicines are revolutionizing healthcare as recently demonstrated by the
Pfizer/BioNTech and Moderna COVID-2019 vaccines, with billions of doses administered …
Pfizer/BioNTech and Moderna COVID-2019 vaccines, with billions of doses administered …